Enterprise Value
112.5M
Cash
32.64M
Avg Qtr Burn
-7.588M
Short % of Float
0.19%
Insider Ownership
27.04%
Institutional Own.
49.26%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Upneeq (RVL-1201) Details Blepharoptosis | Approved Quarterly sales | |
Arbaclofen extended-release (ER) Details Multiple sclerosis, Central nervous system illness | Phase 3 Update |